4//SEC Filing
PRESTRELSKI STEVEN 4
Accession 0001867096-22-000025
CIK 0001867096other
Filed
Feb 23, 7:00 PM ET
Accepted
Feb 24, 4:28 PM ET
Size
11.7 KB
Accession
0001867096-22-000025
Insider Transaction Report
Form 4
PRESTRELSKI STEVEN
Chief Scientific Officer
Transactions
- Exercise/Conversion
Common Stock
2022-02-22$0.69/sh+11,228$7,747→ 581,008 total - Exercise/Conversion
Stock Option (Right to Buy)
2022-02-22−11,228→ 0 totalExercise: $0.69From: 2022-02-22Exp: 2022-02-23→ Common Stock (11,228 underlying) - Sale
Common Stock
2022-02-22$2.42/sh−11,228$27,158→ 569,780 total
Footnotes (3)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- [F2]$2.4188 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.36 to $2.48, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F3]These options are fully vested as of the date hereof.
Issuer
Xeris Biopharma Holdings, Inc.
CIK 0001867096
Entity typeother
Related Parties
1- filerCIK 0001744027
Filing Metadata
- Form type
- 4
- Filed
- Feb 23, 7:00 PM ET
- Accepted
- Feb 24, 4:28 PM ET
- Size
- 11.7 KB